Clinical Trials Logo

Filter by:
NCT ID: NCT04874649 Completed - Asthma in Children Clinical Trials

Balloon Blowing Breathing Exercise in School-age Children With Asthma.

Start date: October 2, 2019
Phase: N/A
Study type: Interventional

This study were to investigate the effects of balloon blowing breathing exercise on respiratory muscle strength and asthma symptoms in school-age children with asthma.

NCT ID: NCT04873362 Recruiting - Breast Cancer Clinical Trials

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Astefania
Start date: May 4, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.

NCT ID: NCT04870723 Completed - Covid19 Clinical Trials

#SafeHandsSafeHearts: An eHealth Intervention for COVID-19 Prevention and Support

COVID-19
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This project seeks to test the efficacy of a brief eHealth intervention in an international randomized controlled trial (RCT) to increase COVID-19 knowledge and protective behaviors, and reduce psychological distress among LGBT people. This project involves enrolling racially diverse samples of lesbian, gay, bisexual and transgender people in three cities, randomizing 900 people (stratified among cisengender men, cisgender women, and transgender people) to either the immediate behavioral intervention or the waitlist control condition. Participants will complete a baseline survey, a follow-up survey 2 weeks post-intervention, and a final survey 2 months after the post-intervention survey. Primary outcomes are COVID-19 transmission knowledge, COVID-19 protective behaviors, and psychological distress.

NCT ID: NCT04869748 Completed - Clinical trials for Stroke Syndrome Sequela Spasticity

Perfetti Method on Upper Extremity Spasticity of Stroke Patient

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

This study objective is to study the immediate effect of Perfetti Method in reducing spasticity of upper extremity in stroke patients at the Department of Physical Medicine,Faculty of Medicine Ramathibodhi Hospital, Thailand. Participants were randomized into experimental group who received therapy according to the Perfetti method, and controlled group who underwent passive stretching exercise. Duration of treatment was 15 minutes for every case, regardless of the treatment. Evaluation of spasticity immediately before and after treatment according to Modified Tardieu scale (MTS) and Modified Ashworth Scale (MAS) by same blinded assessor.

NCT ID: NCT04869033 Completed - COPD Patients Clinical Trials

Effects of Farinelli's Breathing Exercise in COPD Patients

Start date: January 7, 2020
Phase: N/A
Study type: Interventional

This study was to investigate the effect of Farinelli's breathing exercise on pulmonary function, respiratory muscle strength, aerobic capacity, impact of COPD questionnaires, cytokines, and oxidative stress in patients with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT04866706 Completed - Clinical trials for Following Cataract Surgery

Performance and Safety of Routine Cataract Surgery With Visiol

Start date: January 27, 2022
Phase:
Study type: Observational [Patient Registry]

In this clinical investigation, the performance and safety of routine cataract surgery with VISIOL will be assessed

NCT ID: NCT04865510 Completed - Acute Kidney Injury Clinical Trials

Citrate Versus Heparin in Continuous Renal Replacement Therapy :

Start date: February 4, 2019
Phase: N/A
Study type: Interventional

This study is a prospective, multicenter, open-label randomized trial comparing regional citrate anticoagulation (RCA) with heparin-free protocol. The function mode was continuous venovenous hemodiafiltration (CVVHDF) in post-dilution mode. The investigators measured hemodynamic changes at certain time points after starting CRRT (0, 6, 12, 24, 48, 72 hr).Levels of inflammatory cytokine (IL-1β, IL-6, IL-8, IL-10 and TNF-ɑ) were measured at day 1 and day 3

NCT ID: NCT04862663 Recruiting - Clinical trials for Locally Advanced (Inoperable) or Metastatic Breast Cancer

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

CAPItello-292
Start date: May 10, 2021
Phase: Phase 3
Study type: Interventional

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

NCT ID: NCT04859179 Recruiting - Clinical trials for Spinal Muscular Atrophy

Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women

Start date: March 10, 2021
Phase:
Study type: Observational [Patient Registry]

Spinal muscular atrophy (SMA) prenatal carrier screening is recommended by American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG). However, in Thailand, there are no standard protocol for SMA prenatal carrier screening.

NCT ID: NCT04854096 Terminated - Clinical trials for Primary Myelofibrosis

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Start date: January 31, 2023
Phase: Phase 2
Study type: Interventional

This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count <50,000/µL) including subjects with intermediate-2 or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPSS).